HCPCS Level II code J1439 denotes an injection of ferric carboxymaltose measured per 1 mg and is used to bill for intravenous iron therapy. This code matters nationally because intravenous iron is an important treatment for patients with iron deficiency anemia when oral therapy is ineffective or intolerable; accurate coding affects access to infusion therapies, claims adjudication, and cost reporting across outpatient settings.

Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of payer coverage patterns, typical sites of service where ferric carboxymaltose is administered, and common billing practices tied to this HCPCS Level II code. The publication outlines benchmarks for utilization and reimbursement structures, summarizes recent policy updates affecting infusion therapies and injectable iron products, and provides clinical context about indications for intravenous ferric carboxymaltose.

The content focuses on national-level implications for providers, payers, and administrators, highlighting coding considerations, billing workflows, and areas where policy changes may influence coverage and payment for J1439. Data not available in the input will be noted where applicable.